SG11201806930PA - Novel condensed pyrimidine compound or salt thereof - Google Patents
Novel condensed pyrimidine compound or salt thereofInfo
- Publication number
- SG11201806930PA SG11201806930PA SG11201806930PA SG11201806930PA SG11201806930PA SG 11201806930P A SG11201806930P A SG 11201806930PA SG 11201806930P A SG11201806930P A SG 11201806930PA SG 11201806930P A SG11201806930P A SG 11201806930PA SG 11201806930P A SG11201806930P A SG 11201806930PA
- Authority
- SG
- Singapore
- Prior art keywords
- salt
- pyrimidine compound
- novel condensed
- condensed pyrimidine
- present
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- -1 pyrimidine compound Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that 5 is useful for the prevention and/or treatment of RET-related diseases, particularly cancer, based on RET inhibitory activity. The present invention provides a compound represented by Formula (I): 10 wherein A, R 2, and X are as defined in the specification; or a salt thereof. 15
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016031919 | 2016-02-23 | ||
| JP2016140801 | 2016-07-15 | ||
| PCT/JP2017/006672 WO2017146116A1 (en) | 2016-02-23 | 2017-02-22 | Novel condensed pyrimidine compound or salt thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806930PA true SG11201806930PA (en) | 2018-09-27 |
Family
ID=59685768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806930PA SG11201806930PA (en) | 2016-02-23 | 2017-02-22 | Novel condensed pyrimidine compound or salt thereof |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10155768B2 (en) |
| EP (1) | EP3269370B1 (en) |
| JP (1) | JP6273075B1 (en) |
| KR (1) | KR102356212B1 (en) |
| CN (1) | CN108697714B (en) |
| AU (1) | AU2017222908B2 (en) |
| BR (1) | BR112018016724B1 (en) |
| CA (1) | CA3015484C (en) |
| CY (1) | CY1123353T1 (en) |
| DK (1) | DK3269370T3 (en) |
| ES (1) | ES2775751T3 (en) |
| HR (1) | HRP20200352T1 (en) |
| HU (1) | HUE049228T2 (en) |
| IL (1) | IL261107B2 (en) |
| LT (1) | LT3269370T (en) |
| MD (1) | MD3269370T2 (en) |
| ME (1) | ME03669B (en) |
| MX (1) | MX389450B (en) |
| MY (1) | MY199511A (en) |
| PH (1) | PH12018501716A1 (en) |
| PL (1) | PL3269370T3 (en) |
| PT (1) | PT3269370T (en) |
| RU (1) | RU2770727C2 (en) |
| SG (1) | SG11201806930PA (en) |
| SI (1) | SI3269370T1 (en) |
| TW (1) | TWI687422B (en) |
| WO (1) | WO2017146116A1 (en) |
| ZA (2) | ZA201805491B (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693720B (en) | 2010-05-20 | 2019-01-18 | 阵列生物制药公司 | Macrocyclic compound as TRK kinase inhibitor |
| PT3319959T (en) | 2015-07-06 | 2021-12-06 | Alkermes Inc | Hetero-halo inhibitors of histone deacetylase |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| EP3322706B1 (en) | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| MA41559A (en) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | CONDENSED PYRIMIDINE COMPOUND OR A SALT THEREOF |
| HRP20200352T1 (en) | 2016-02-23 | 2020-06-12 | Taiho Pharmaceutical Co., Ltd. | NEW CONDENSED PYRIMIDINE COMPOUND OR ITS SALT |
| JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| MX390582B (en) | 2016-12-28 | 2025-03-20 | Dart Neuroscience Llc Star | SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PHOSPHODIESTERASE 2 (PDE2) INHIBITORS |
| CA3049443A1 (en) | 2017-01-11 | 2018-07-19 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CN110267960B (en) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors |
| JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
| JP7152471B2 (en) | 2017-08-07 | 2022-10-12 | ロダン・セラピューティクス，インコーポレーテッド | Bicyclic inhibitor of histone deacetylase |
| CA3073375A1 (en) | 2017-08-21 | 2019-02-28 | Taiho Pharmaceutical Co., Ltd. | Fusion protein of dctn1 protein with ret protein |
| TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
| TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
| KR102794907B1 (en) | 2017-11-27 | 2025-04-14 | 다트 뉴로사이언스, 엘엘씨 | Substituted furanopyrimidine compounds as PDE1 inhibitors |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| TW201938169A (en) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[3,4-d]pyrimidine compounds as RET kinase inhibitors |
| CN111971286B (en) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | Substituted pyrrolo[2,3-d]pyrimidine compounds as RET kinase inhibitors |
| ES2922314T3 (en) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Fused Heterocyclic Compounds as RET Kinase Inhibitors |
| PT3909584T (en) | 2019-01-11 | 2024-01-12 | Taiho Pharmaceutical Co Ltd | PYRIMIDINE COMPOUND OR A SALT THEREOF |
| KR20210142154A (en) | 2019-03-21 | 2021-11-24 | 옹쎄오 | DBAIT molecules in combination with kinase inhibitors for the treatment of cancer |
| MX2021013146A (en) * | 2019-05-13 | 2022-01-24 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof. |
| CN114761006A (en) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | Methods of treating cancer resistant to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US11373425B2 (en) | 2020-06-02 | 2022-06-28 | The Nielsen Company (U.S.), Llc | Methods and apparatus for monitoring an audience of media based on thermal imaging |
| CN116368136B (en) * | 2020-07-15 | 2025-09-05 | 大鹏药品工业株式会社 | EGFR inhibitors |
| EP4183395A4 (en) * | 2020-07-15 | 2024-07-24 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
| US11763591B2 (en) | 2020-08-20 | 2023-09-19 | The Nielsen Company (Us), Llc | Methods and apparatus to determine an audience composition based on voice recognition, thermal imaging, and facial recognition |
| US11553247B2 (en) | 2020-08-20 | 2023-01-10 | The Nielsen Company (Us), Llc | Methods and apparatus to determine an audience composition based on thermal imaging and facial recognition |
| TW202233625A (en) | 2020-11-18 | 2022-09-01 | 美商傳達治療有限公司 | Fgfr inhibitors and methods of making and using the same |
| CN116867492A (en) * | 2020-11-20 | 2023-10-10 | 赫尔森保健股份公司 | Use 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl) )-7H-pyrrolo[2,3-D]pyrimidine-5-carboxamide method for treating tumors |
| ES3010375T3 (en) * | 2020-11-20 | 2025-04-02 | Taiho Pharmaceutical Co Ltd | Crystalline forms of 4-amino-n-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carboxamide, methods of preparation, and uses thereof |
| JP2024500628A (en) * | 2020-11-20 | 2024-01-10 | ヘルシン ヘルスケア ソシエテ アノニム | 4-Amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H- for tumor treatment How to use pyrrolo[2,3-D]pyrimidine-5-carboxamide |
| CA3199714A1 (en) * | 2020-11-20 | 2022-05-27 | Isao Miyazaki | Brain-migrating tumor therapeutic agent containing fused pyrimidine compound as active ingredient |
| CA3234317A1 (en) | 2021-10-22 | 2023-12-14 | Wa Xian | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues |
| WO2025193959A1 (en) | 2024-03-13 | 2025-09-18 | Fountain Therapeutics Inc. | Methods & compositions for treating dermal atrophy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665721A (en) | 1995-06-07 | 1997-09-09 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
| MXPA06005578A (en) | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Pyrrolopyrimidine compounds useful in treatment of cancer. |
| ES2527118T3 (en) | 2003-12-19 | 2015-01-20 | Plexxikon Inc. | Ret modulator development compounds and procedures |
| BRPI0514094A (en) | 2004-08-02 | 2008-05-27 | Osi Pharm Inc | compound, composition, and method of treating hyperproliferative disorder |
| JP5237108B2 (en) * | 2005-12-08 | 2013-07-17 | アボット・ラボラトリーズ | 9-membered heterobicyclic compounds as protein kinase inhibitors |
| WO2011018894A1 (en) | 2009-08-10 | 2011-02-17 | Raqualia Pharma Inc. | Pyrrolopyrimidine derivatives as potassium channel modulators |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| AU2013210403B2 (en) * | 2012-01-19 | 2016-01-14 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| GB201201566D0 (en) | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| US10031968B2 (en) | 2012-10-11 | 2018-07-24 | Veveo, Inc. | Method for adaptive conversation state management with filtering operators applied dynamically as part of a conversational interface |
| WO2014130975A1 (en) | 2013-02-22 | 2014-08-28 | Bastian Boris C | Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets |
| ES2646019T3 (en) * | 2013-05-14 | 2017-12-11 | Nerviano Medical Sciences S.R.L. | 6-amino-7-deaza-purine derivatives, a process for its preparation and its use as kinase inhibitors |
| CA2921208C (en) | 2013-08-12 | 2018-02-20 | Taiho Pharmaceutical Co., Ltd. | Fused pyrimidine compound or salt thereof |
| WO2015078417A1 (en) | 2013-11-29 | 2015-06-04 | 四川好医生药业集团有限公司 | Pyrrolopyrimidine compound and use thereof in preparation of hypoglaecemic drug |
| EP3345907B1 (en) * | 2015-09-01 | 2020-04-22 | Taiho Pharmaceutical Co., Ltd. | Pyrazolo[3,4-d]pyrimidine compounds or salts thereof |
| MA41559A (en) | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | CONDENSED PYRIMIDINE COMPOUND OR A SALT THEREOF |
| HRP20200352T1 (en) * | 2016-02-23 | 2020-06-12 | Taiho Pharmaceutical Co., Ltd. | NEW CONDENSED PYRIMIDINE COMPOUND OR ITS SALT |
-
2017
- 2017-02-22 HR HRP20200352TT patent/HRP20200352T1/en unknown
- 2017-02-22 KR KR1020187027127A patent/KR102356212B1/en active Active
- 2017-02-22 EP EP17756554.6A patent/EP3269370B1/en active Active
- 2017-02-22 RU RU2018133000A patent/RU2770727C2/en active
- 2017-02-22 MY MYPI2018702960A patent/MY199511A/en unknown
- 2017-02-22 ES ES17756554T patent/ES2775751T3/en active Active
- 2017-02-22 DK DK17756554.6T patent/DK3269370T3/en active
- 2017-02-22 MX MX2018010176A patent/MX389450B/en unknown
- 2017-02-22 PT PT177565546T patent/PT3269370T/en unknown
- 2017-02-22 BR BR112018016724-0A patent/BR112018016724B1/en active IP Right Grant
- 2017-02-22 WO PCT/JP2017/006672 patent/WO2017146116A1/en not_active Ceased
- 2017-02-22 CN CN201780012909.0A patent/CN108697714B/en active Active
- 2017-02-22 TW TW106105968A patent/TWI687422B/en active
- 2017-02-22 SG SG11201806930PA patent/SG11201806930PA/en unknown
- 2017-02-22 IL IL261107A patent/IL261107B2/en unknown
- 2017-02-22 ME MEP-2020-46A patent/ME03669B/en unknown
- 2017-02-22 HU HUE17756554A patent/HUE049228T2/en unknown
- 2017-02-22 SI SI201730182T patent/SI3269370T1/en unknown
- 2017-02-22 PL PL17756554T patent/PL3269370T3/en unknown
- 2017-02-22 AU AU2017222908A patent/AU2017222908B2/en active Active
- 2017-02-22 CA CA3015484A patent/CA3015484C/en active Active
- 2017-02-22 LT LTEP17756554.6T patent/LT3269370T/en unknown
- 2017-02-22 MD MDE20180076T patent/MD3269370T2/en unknown
- 2017-02-22 JP JP2017519012A patent/JP6273075B1/en active Active
- 2017-09-19 US US15/708,917 patent/US10155768B2/en active Active
-
2018
- 2018-08-13 PH PH12018501716A patent/PH12018501716A1/en unknown
- 2018-08-16 ZA ZA201805491A patent/ZA201805491B/en unknown
- 2018-11-01 US US16/177,844 patent/US10807986B2/en active Active
-
2019
- 2019-08-13 ZA ZA2019/05332A patent/ZA201905332B/en unknown
-
2020
- 2020-03-26 CY CY20201100282T patent/CY1123353T1/en unknown
- 2020-05-13 US US15/930,554 patent/US11046696B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806930PA (en) | Novel condensed pyrimidine compound or salt thereof | |
| SG11201901061QA (en) | Heterocyclic compound | |
| PH12019500480A1 (en) | Pyridine compound | |
| SA520412335B1 (en) | Oxy-fluoropiperidine derivatives as kinase inhibitor | |
| MX2021007432A (en) | Compounds and compositions for inhibiting the activity of shp2. | |
| PH12017502407A1 (en) | Fused pyrimidine compound or salt thereof | |
| MX2016003582A (en) | Compound inhibiting kinase activities of btk and/or jak3. | |
| MY196186A (en) | Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor | |
| PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
| PH12016500225B1 (en) | Novel quinoline-substituted compound | |
| PH12019501690A1 (en) | Pyrimidine compound and pharmaceutical use thereof | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| TW201613896A (en) | Novel 2,5-substituted pyrimidines | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| MX2017000208A (en) | Quinolizinone derivatives as pi3k inhibitors. | |
| NZ752823A (en) | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | |
| MX379373B (en) | Heterocyclic sulfonamide derivative and medicine containing same | |
| NZ727715A (en) | Novel heterocyclic compounds having prs enzyme inhibitory effect | |
| PH12019502046A1 (en) | Pyrrolotriazine derivatives as kinase inhibitor | |
| MY197042A (en) | Compounds | |
| MX385475B (en) | Pyridoquinazoline derivatives useful as protein kinase inhibitors | |
| NZ748746A (en) | Pyrazolopyrimidine derivatives as kinase inhibitor |